Core Viewpoint - Northeast Pharmaceutical is currently in a critical period of deep adjustment and transformation in the pharmaceutical industry, emphasizing the importance of each step in its development [1] Group 1: R&D and Strategic Transformation - Northeast Pharmaceutical is a significant drug production and export base in China, focusing on innovation-driven strategies and core business enhancement, achieving important results in R&D breakthroughs and quality improvement [2] - The company has increased R&D investment, aiming to accelerate the transition of innovative results from the laboratory to clinical applications [2] - The DCTY0801 injection, developed by its subsidiary, is set to undergo clinical trials for specific types of high-grade brain gliomas, marking a substantial breakthrough in cancer treatment innovation [2] - The acquisition of a 70% stake in DCTY0801's developer allows Northeast Pharmaceutical to quickly enter the cell therapy field, positioning it as a key platform for innovative drug development [3] - The company is committed to building a systematic and scalable talent cultivation system to enhance its R&D capabilities and facilitate its strategic shift from chemical pharmaceuticals to biological innovative drugs [3] Group 2: Quality Assurance and Market Expansion - Strong R&D capabilities provide essential support for product quality enhancement, which is crucial for global market competition [4] - The company’s core raw material product, Phosphomycin Amide, received the European Pharmacopoeia suitability certificate (CEP) in 2025, becoming the first domestic company to achieve this certification, enhancing its brand image and competitiveness in the international high-end market [4] - Northeast Pharmaceutical successfully passed a surprise inspection by the FDA, demonstrating its leading quality control system across the entire production and management chain [4] - The company is enhancing its quality management capabilities to support its expansion in both domestic and international markets [4] Group 3: Business Diversification and Value Enhancement - Northeast Pharmaceutical is expanding into related business areas, developing health food products based on the concept of "medicinal food homology" and launching a skincare brand, "Qifangyuan," to enter the beauty market [6] - The company’s diversification efforts are based on professional technology and aim to extend the value chain around the core of "health" [6] - The "Qifangyuan" brand integrates pharmaceutical technology and standards into skincare product development, showcasing the company's innovative approach [6] - Northeast Pharmaceutical is committed to optimizing its health product matrix and exploring comprehensive health services to create additional growth points [6] Group 4: Recognition and Achievements - The company’s improved business layout and solid operational results have enhanced its overall strength, leading to recognition from various sectors [7] - In 2025, Northeast Pharmaceutical was included in the list of recommended "National Intellectual Property Demonstration Enterprises" in Liaoning Province and re-certified as a national high-tech enterprise [7] - The company received the title of "Top 100 Pharmaceutical Industrial Enterprises by Revenue" for the 2024-2025 period in industry evaluations [7]

Core Viewpoint - The company is undergoing a critical period of deep adjustment and transformation in the pharmaceutical industry, emphasizing the importance of each step in its development and focusing on innovation, quality, talent strategy, and diversified layout to drive transformation and upgrade [1] R&D-Driven Strategic Transformation - Northeast Pharmaceutical is a significant drug production and export base in China, focusing on innovation and core business development, achieving important results in R&D breakthroughs and quality improvement [1] - The company has increased R&D investment, accelerating the transition of innovative results from the laboratory to clinical applications [2] - The DCTY0801 injection, developed by its subsidiary Dingcheng Peptide Source, received approval for clinical trials targeting specific types of high-grade brain gliomas, marking a substantial breakthrough in innovative drug development for tumor treatment [1][2] Quality Assurance for Market Expansion - Strong R&D capabilities have provided essential support for product quality enhancement, with quality being described as the lifeline for pharmaceutical companies [2] - The company's core raw material product, phosphomycin aminobutyric acid, received the European Pharmacopoeia suitability certificate (CEP) in 2025, becoming the first domestic company to obtain this certification, enhancing the brand image and competitiveness of Chinese raw materials in the international high-end market [3] - The company passed a surprise inspection by the FDA with a "zero defect" score, demonstrating its leading quality control system across the entire production and management chain [3] Comprehensive Value Enhancement through Layout - While deepening its core business, the company is actively expanding into related fields based on its professional advantages in pharmaceutical R&D and production [4] - The company has developed four health biscuits based on the concept of "food and medicine homology," enriching its existing product matrix in food and health products [4] - The launch of the skincare brand "Qifangyuan" represents the company's entry into the beauty sector, integrating pharmaceutical technology with skincare product development [4] Recognition and Achievements - The company's comprehensive business layout and solid operational results have enhanced its overall strength, leading to recognition from various sectors [5] - In 2025, Northeast Pharmaceutical was included in the list of "National Intellectual Property Demonstration Enterprises" recommended by Liaoning Province and re-certified as a national high-tech enterprise [5] - The company was awarded the title of "Top 100 Pharmaceutical Industrial Enterprises by Revenue for 2024-2025" in industry evaluations [5]